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doi:10.1016/j.kjms.2010.12.007Abstract The purpose of this study was to compare the usefulness of the nucleic acid ampli-
fication (NAA) test against conventional tests under normal laboratory operational conditions.
The NAA test was performed on the first sputum specimen of all patients. Liquid media culture,
solid media culture, and ZiehleNeelsen stain for an acid-fast bacilli (AFB) smear were
performed on three sputum specimens. The results were calculated using the gold standard
of either the culture results or the clinical diagnosis. Of the 593 patients tested, 151 (25.5%)
were diagnosed with pulmonary tuberculosis. The sensitivity of the first specimen only was
64% for the NAA test, 54% for the AFB smear, 77% for BACTEC MGIT 960 culture, 40% for
Lowestain-Jensen (LJ) culture, and 25% for 7H11 culture. The sensitivity when using all three
specimens increased to 63% for AFB smear, 87% for BACTEC MGIT 960 culture, 51% for LJ
culture, and 40% for 7H11 culture. The specificity was 100% for all culture tests, 99% for the
AFB smear, and 99.5% for NAA test. The mean turnaround time was 1.34 days for NAA, 0.59
days for AFB smear, 11 days for BACTEC MGIT 960 culture, 23 days for LJ culture, and 20 days
for 7H11 culture. We conclude that the sensitivity of NAA is still far from ideal, and the test is
not cost effective. Thus, the COBAS AMPLICOR PCR system is not suitable for routine use in
microbiology laboratories.f InternalMedicine,Buddhist TzuChiGeneralHospital, 707Chung-YangRoad, Section3,Hualien,Taiwan.
.tw (J.-J. Lee).
vier Taiwan LLC. All rights reserved.
NAA test for TB diagnosis 139摘要 本研究是比較在實驗室正常運行條件下進行核酸擴增技術(Nucleic acid amplification，
NAA)與傳統培養方法對於結核病診斷的評估。 NAA 的測試只做在所有病人的第一套痰檢體。液
體培養基（BACTEC MGIT 960），固體培養基(Lowenstein-Jensen，LJ與7H11)與抗酸染色塗片
則進行了3套痰檢體。診斷為肺結核的黃金標準是指培養結果或臨床診斷。在593病人中，151
（25.5％）診斷為肺結核。在NAA檢測方法中第一套檢體的靈敏度(sensitivity)為64％，抗酸染色
塗片為54％， BACTEC MGIT 960為77％， LJ為40％和7H11為 25％。在所有三套檢體中靈敏度則
提高為抗酸染色塗片為63％、BACTEC MGIT 960 為87％、LJ為51％和7H11為40％。特異性(spec-
ificity)在所有的培養方法為 100％、抗酸染色塗片為99％和 NAA 為99.5％。平均迴轉時間
（TAT）NAA為 1.34天，抗酸染色塗片為0.59天， BACTE MGIT 960為11天、LJ為23天、7H11為
20天。我們的結論是NAA的敏感度遠遠不夠理想，也不符合成本效益。因此 COBAS AMPLICOR
PCR是不適合常規實驗室使用。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Tuberculosis (TB) remains a serious public health threat
worldwide. According to the World Health Organization,
there were an estimated 9.4 million new TB cases with 1.8
million deaths in 2008 [1]. The first priority in TB control
strategy is early detection and reporting [2]. This allows
prompt initiation of multiple-drug treatment, which rapidly
reduces infectiousness and interrupts further transmission
of Mycobacterium tuberculosis [2]. The conventional
laboratory diagnosis tests for M tuberculosis depend on
acid-fast bacilli (AFB) smear and culture. AFB smear is
inexpensive, quick, and easy to perform. It has a relatively
low sensitivity of 61.3e63.4% but a relatively high speci-
ficity of 97.3% [3]. However, the AFB smear comes with
some limitations: (1) a positive AFB smear requires the
presence of at least 10,000 organisms per milliliter of
sputum; (2) it cannot distinguish M tuberculosis from other
nontuberculous mycobacterial species (NTM) [4]. Although
the isolation of M tuberculosis by culture is considered the
most accurate and sensitive test, and this approach is able
to detect as low as 10 organisms per milliliter of sputum [4],
the test is labor intensive and time consuming, as solid
media cultures may take 6e8 weeks to yield results.
However, the new rapid mycobacterial culturing system
BACTEC MGIT 960 has a mean time for detecting growth
that ranges from 9.3 days to 14.4 days [5e7].
In recent years, progress has been made in the early
diagnosis of TB through application of molecular biology
techniques [8e10]. Recently, nucleic acid amplification
(NAA) tests have been recommended for the rapid detection
of M tuberculosis by various Centers for Disease Control
(CDC) [5,11]. The performance characteristics of the NAA
tests against the gold standard of TB culture have been well
studied. In a review by Roth et al. [12], the sensitivity and
specificity of five trials of in-house-designed NAA tests
and four trials of a commercial kit, varied from 75% to 91%
and from 92% to 99%, respectively . The sensitivity of the NAA
test is also known to be lower in smear-negative samples.
The COBAS AMPLICOR PCR (Roche Diagnostics Systems),
which uses the same primers, probe, and internal control as
the Amplicor Mycobacterium tuberculosis-PCR (MTB-PCR),
is performed on the Cobas Amplicor Analyzer, a fully
automated, integrated system that performs amplification,
detection, and reporting of results without user interven-
tion [13]. Although NAA tests had undergone extensivetrials in clinical laboratories, their utility during routine
clinical use has not been examined, and it is uncertain how
NAA tests will perform in normal clinical microbiology
laboratories [14].
The purpose of this prospective study was to compare
the utility of the COBAS AMPLICOR PCR system against
AFB smears, culture, and clinical diagnoses of pulmonary
TB under normal laboratory operating conditions; the
aims were to determine the overall performance and
turnaround time (TAT) and to estimate the contribution
that each test is able to provide to a rapid and accurate
result.
Methods
Patient population
The population studied consisted of inpatients suspected of
having TB at Tzu Chi General Hospital from September 2006
to August 2007. Patients were excluded from the study if
they had received antimycobacterial treatment for 14 days
or more. This study was reviewed by National Tuberculosis
Association, Taiwan.
AFB smears
Smears were examined for AFB. All AFB smears were stained
by the ZiehleNeelsen stain and examined with a light
microscope.
Culture systems
BACTEC MGIT 960
The BACTEC MGIT 960 culture tube contains 7 mL of Mid-
dlebrook 7H9 broth base. After inoculation of each tube
with 0.5 mL of the processed specimen, the tubes were
incubated at 37C in the BACTEC MGIT 960 instrument and
were monitored automatically every 60 minutes for an
increase in fluorescence. The cultures were tested either
until found to be positive or for 42 days.
Solid media
All specimens were inoculated onto conventional solid
media, which consisted of one LJ slant and one 7H11 agar
plate. Solid media were incubated at 37C in an atmosphere
140 C.-B. Lin et al.of 5e10% CO2 for 8 weeks and were inspected twice weekly
or until mycobacterial colonies were seen.
Identification of the Mycobacterium species
Identification of the Mycobacterium species was based on
colony morphology, colony pigmentation, rate of growth on
conventional solid media, and the results of biochemical
tests (such as the niacin test and the nitrate test). The
outcome was limited to differentiating M tuberculosis from
NTM.
NAA test
The COBAS AMPLICOR PCR method
Roche COBAS AMPLICOR PCR was carried out according to
the manufacturer’s instructions.
Patients’ clinical evaluation
Clinical assessments included the patient’s medical histo-
ries, chest X-rays, pathologies, laboratory culture results,
and the patient’s responses to therapy. All of the records
were carefully reviewed, with the aim of setting up
a combination of culture and clinical diagnosis as the gold
standard.
Statistical analysis
TAT was calculated from the time the first specimen was
received in the laboratory to the time the final result was
available for each test (including weekends and holidays).
For cultures, TAT did not include the time needed for
identification. The sensitivity, specificity, positive predic-
tive values, and negative predictive values were calculated
using either the culture results or the clinical diagnosis as
a gold standard.
Results
From September 2006 to August 2007, 593 patients were
enrolled into this prospective study. We had planned to
collect three sequential sputum specimens from each
patient. However, we were able to collect only three
sputum specimens from 470 patients (79.3%), with 74
(12.5%) patients and 49 (8.3%) patients providing two and
one sputum specimens, respectively.
Of the 593 patients tested, 151 (25.5%) were diagnosed
as having active pulmonary TB. The results of the NAA tests
for the first sputum specimen were compared with the AFB
smears and cultures of all specimens (Table 1). No single
test had 100% detection for TB patients. Of the 151 TB
patients, BACTEC MGIT 960 detected 87% (131/151) and
NAA (first specimen only) detected 64% (97/151), whereas
solid cultures (LJ and 7H11) and AFB smears detected 54%
(82/151) and 63% (95/151), respectively. Using all speci-
mens available, the three culture methods identified 89%
(134/151) of pulmonary TB patients. AFB smear had
a specificity of 99% and a sensitivity of 63% (Table 1). NAA
had a specificity of 99.5% and a sensitivity of 64%. Overall,the specificity of all the culture assays was 100%. NAA was
able to identity 87% (83/95) of TB patients with at least one
or more smear-positive specimens and 25% (14/56) of the
TB patients with three smear-negative specimens.
Among the three patients with false-positive AFB
smears, two had positive cultures for NTM. Two patients
had NAA-positive, smear-negative, and culture-negative
specimens and had a clinical diagnosis of a chest disease
other than TB. They were considered as false positives for
the NAA test.
Among the 17 patients with false-negative cultures, six
patients had culture-positive specimens collected before or
after the study specimens were collected. Another two
patients had NAA-positive, smear-positive specimens with
clinical and radiographic evidence of current TB. One
patient had an NAA-positive, smear-negative specimen with
clinical and radiographic evidence of current TB. The
remaining eight patients were NAA negative, smear nega-
tive, and culture negative but had clinical and radiographic
evidence of current TB.
The first specimen collected was the only specimen
tested with NAA and all other tests, allowing a direct
comparison of performance. NAA detected 64% (97/151) of
TB patients from this specimen, whereas BACTEC MGIT 960
detected 77% (117/151). The sensitivity of the other tests
was less than 60% (AFB smear: 54%, LJ: 40%, and 7H11:
25%). All culture tests combined detected 79% (120/151) of
TB patients with the first specimen. Using first-specimen
testing alone, NAA detected eight TB patients who were
missed by all other assays, whereas BACTEC MGIT 960 alone
detected 19. Together, BACTEC MGIT 960 and NAA detected
85% (128/151) of all TB patients using first-specimen testing
alone.
Testing of the second and third specimens progressively
increased the cumulative sensitivity of all tests. Cumulative
sensitivities for second and third specimens were 59.6% and
62.9%, respectively, for AFB smears; 84.1% and 86.8%,
respectively, for BACTEC MGIT 960; 49.0% and 51.0%,
respectively, for LJ; and 37.1% and 40.4% for 7H11 (Fig. 1).
Using all tests, 87% of TB patients were detected by testing
the first specimen, 89% by the first and second specimens,
and 91% by all three specimens.
The mean TAT for the series of three specimens was
calculated for each TB patient from the time the first
specimen was received in the laboratory to the time the
positive result was available. The timeline of these positive
results is presented in Fig. 2. The difference in TAT
between liquid media and solid media was significant, as
was the reduction in TAT between nonculture techniques
(AFB smear and NAA) and liquid media culture. The last
positive result detected by each test took 9 days for AFB
smear, 6 days for NAA, 39 days for BACTEC MGIT 960, 60
days for LJ, and 38 days for 7H11.
By comparing AFB smear with NAA for rapid diagnosis of
TB, NAA had a slightly higher sensitivity and specificity
(Table 1). NAA identified 14 additional cases of TB and gave
negative results for all smear-positive specimens that grew
NTM. The cost of COBAS AMPLICOR PCR for reagents and
related expenses was estimated to be US$20 per test. The
total cost for NAA examination of 593 specimens (one
specimen per patient) was US$11,860. By using NAA and
AFB smear, diagnosis of TB was made in 14 additional
Table 1 Performance characteristics of the AFB smear, NAA test, and various culture methods
Pulmonary TB status Sensitivity (%) Specificity (%) PPV (%) NPV (%) Mean TAT (d)
Positive (nZ151) Negative (nZ442)
AFB smear
Positive 95 3a 63 99 97 89 0.59
Negative 56 439
NAA test
Positive 97 2 64 99.5 98 89 1.34
Negative 54 440
BACTEC MGIT 960
Positive 131 0 87 100 100 96 11
Negative 20 442
LJ
Positive 77 0 51 100 100 86 23
Negative 74 442
7H11
Positive 61 0 40 100 100 83 20
Negative 90 442
Total culture
Positive 134 0 89 100 100 96 11
Negative 17 442
a Two of them are nontuberculous mycobacterial species.
AFBZ acid-fast bacilli; NAAZ nucleic acid amplification; NPVZ negative predictive value; PPVZ positive predictive value; TATZ
turnaround time; TBZ tuberculosis.
NAA test for TB diagnosis 141patients and was excluded in both smear-positive patients
for whom the cultures grew NTM. On the other hand, two
patients were misdiagnosed by NAA as having TB (Table 1).
Therefore, the overall benefit of using NAA was that it
provided an additional 14 correct clinical decisions, making
the incremental cost of each additional correct diagnosis
US$847, which is not cost effective.Discussion
The findings presented here provide information on the
performance of the COBAS AMPLICOR PCR test and conven-
tional tests for the diagnosis of pulmonary TB by examining
sputum specimens over a 1-year period in a geographic region
with an intermediate incidence of TB (60e70 new cases
annually/100,000 population). The performance of AFB
smear here was as expected; the TAT was rapid, but the
sensitivity was low (the cumulative sensitivity was 63% on allFigure 1. Cumulative sensitivity of acid-fast bacilli smear, vari
(white bar), the first and second specimens (gray bar), and all threthree specimens), and the negative predictive value was 89%.
The mean time required for an AFB smear to yield positive
results in this study was 0.59 days, which is within the 1-day
goal published by the CDC [2]. The BACTEC MGIT 960 used in
this study was overall the most sensitive test, detecting 87%
of positives using three specimens and was the most rapid
culture test. In this study, the mean TATwas 11 days, which is
within the 14-day goal published by the CDC [2]. The
performances of LJ and 7H11 solid media were poor in this
study and they had sensitivities of 51% and 40%, respectively.
The TAT was slow, with mean TATs of 23 days and 20 days,
respectively. Only three patients were diagnosed by culturing
on solid media and not by liquid culture media.
In our laboratory routine, the COBAS AMPLICOR PCR is
performed twice a week. The mean time required for the
NAA to yield positive results in this study was 1.34 days,
which is within the 48-hour goal published by the CDC [2].
The COBAS AMPLICOR PCR had a low sensitivity of 64% and
a high specificity of 99.5%.test
ous culture methods, and the NAA test for the first specimen
e specimens (black bar). NAAZ nucleic acid amplification.
Figure 2. Turnaround times for AFS, the various culture methods, and the NAA test. The results are expressed as the percentage
of tuberculosis patients who were reported as positive by the day indicated. NAAZ nuclear acid amplification; AFS = acid-fast
bacilli smear.
142 C.-B. Lin et al.Surprisingly, the sensitivity of the COBAS AMPLICOR, as
calculated in this study, (64%) is lower than that reported in
many other studies (Bodmer et al. [15], 92.6%; Rajalahti
et al. [16], 83%; Wang and Tay [17], 96.1%; Reischl et al.
[18], 83.5%; Bogard et al. [19], 85.2%; Levidiotou et al. [13],
84.5%; and Scarparo et al. [20], 94.2%). The test maximizes
specificity at the cost of sensitivity. One study conducted in
Lusaka reported a sensitivity of 55% [21]. However, this
study used a low-cost “in-house” one-tube nested PCR. The
possible explanations for the low sensitivity using COBAS
AMPLICOR PCR were (1) poor efficacy of DNA extraction
from specimens; (2) a low bacterial load in the specimens;
(3) the presence of substances that inhibit amplification;
(4) an uneven distribution of mycobacterial DNA in the test
sample; or (5) technical errors [13]. The false-positive NAA
result rate was very low (1.3%, 2/151)donly two patients in
this study. False-positive NAA results are usually because of
laboratory cross-contamination.
On the basis of current evidence, the high specificity of
the COBAS AMPLICOR PCR system is sufficient as a diag-
nostic tool for the detection and identification of TB.
However, the system’s low sensitivity is unable to exclude
the disease with certainty.
The accuracy of the NAA test for pulmonary TB seems to
be similar to that of the AFB smear, namely, high specificity
and low sensitivity. This similarity makes NAA tests less
useful in practice because they lack traits that complement
the properties of the AFB smear.
There is an uneven shedding of M tuberculosis in
patient’s sputa, and therefore, the CDC and the American
Thoracic Society recommend obtaining three sequentialsputum specimens for AFB smear and culture to diagnose
pulmonary TB [4,22]. The results of this study demonstrate
the need for multiple specimens to diagnose TB, especially
when depending on culture techniques. The detection rate
by all culture tests increased from 79% using the first
specimen alone to 89% when using all three specimens.
In the present study, the incremental cost of adding NAA
to the conventional tests for diagnosis of TB was US$847 per
additional correct clinical decision, which is not cost
effective. The high cost is likely to be an impediment to
implementation for many laboratories. According to the CDC
and the American Thoracic Society, NAA tests are able to
enhance diagnostic certainty, but they do not replace smear
and culture. NAA tests can greatly increase confidence in the
clinical diagnosis while culture growth is pending, but they
do not replace clinical judgment [14]. NAA tests also help to
identify TB caused by NTM infection, a feature that might be
helpful in populations with high rates of NTM. For AFB
smearepositive pulmonary cases, an NAA test provides rapid
confirmation that the infecting Mycobacterium isolates are
from the M tuberculosis complex. These two rapid tests can
facilitate decisions about initiating treatment for TB or
a non-TB pulmonary infection [14].
The main limitation of the study was the absence of all
three respiratory specimens in some patients. This is
a prospective study. All patients were requested to provide
three sputum specimens, but some patients failed to do so. If
all patients had sent three sputum specimens, the sensitivity
of conventional tests may have been somewhat higher.
The conclusion can be made that, although COBAS
AMPLICOR PCR provides a rapid and specific detection
NAA test for TB diagnosis 143system for M tuberculosis in sputum specimens, the sensi-
tivity of the NAA is still far from ideal and its use is not cost
effective as part of a battery of tests. The COBAS AMPLICOR
PCR does not seem to be suitable for routine use in clinical
microbiology laboratories at the present time.
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